Molecular mechanisms of tolerance to and withdrawal of GABAA receptor modulators

European Neuropsychopharmacology

Volumn 13, Issue 6, 2003, Pages 411-423

  Biggio, Giovanni ^a   Dazzi, Laura ^b   Biggio, Francesca ^b   Mancuso, Luisa ^b   Talani, Giuseppe ^b   Busonero, Fabio ^b   Mostallino, Maria Cristina ^b   Sanna, Enrico ^b   Follesa, Paolo ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b NONE

Author keywords

Dopamine; Gene expression; Microdialysis; Neuroactive steroids

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 ETHYL 6,7 DIMETHOXY BETA CARBOLINE 3 CARBOXYLIC ACID METHYL ESTER; ALCOHOL; BENZODIAZEPINE DERIVATIVE; DIAZEPAM; FINASTERIDE; FLUMAZENIL; PROGESTERONE; STEROID; ZALEPLON; ZOLPIDEM;

ALCOHOL WITHDRAWAL; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVITY; CELL POPULATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG DEPENDENCE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG SELECTIVITY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; GENE EXPRESSION REGULATION; LONG TERM EXPOSURE; MALE; NERVE CELL; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; RAT; RECEPTOR INTRINSIC ACTIVITY; XENOPUS LAEVIS;

EID: 0242551385     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2003.08.002     Document Type: Article

References (85)

1. Arbilla S., Depoortere H., George P., Langer S.Z. Pharmacological profile of the imidazopyridine zolpidem at benzodiazepine receptors and electrocorticogram in rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 330:1985;248-251.
2. Azzolina B., Ellsworth K., Andersson S., Geissler W., Bull H.G., Harris G.S. Inhibition of rat α-reductases by finasteride: evidence for isozyme differences in the mechanism of inhibition. J. Steroid Biochem. Mol. Biol. 61:1997;55-64.
3. 2 inhalation. Eur. J. Pharmacol. 261:1994;317-320.
4. A receptor function after acute stress. Neuroendocrinology. 63:1996;166-172.
5. Barbaccia M.L., Roscetti G., Trabucchi M., Purdy R.H., Mostallino M.C., Concas A., Biggio G. The effects of inhibitors of GABAergic transmission and stress on brain and plasma allopregnanolone concentrations. Br. J. Pharmacol. 20:1997;1582-1588.
6. A receptor function, and anxiety: a study in menopausal women. Psychoneuroendocrinology. 25:2000;659-675.
7. A receptors. Classification on the basis of subunit structure and receptor function. Pharmacol. Rev. 50:1998;291-313.
8. Beer B., Ieni J.R., Wu W.H., Clody D., Amorusi P., Rose J., Mant T., Gaudreault J., Cato A., Stern W. A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic. J. Clin. Pharmacol. 34:1994;335-344.
9. Bradberry C.W., Lory J.D., Roth R.H. The anxiogenic β-carboline FG 7142 selectively increases dopamine release in the rat prefrontal cortex as measured by microdialysis. J. Neurochem. 56:1991;748-752.
10. Braestrup C., Schmiechen R., Neef G., Nielsen M., Petersen E.N. Interaction of convulsive ligands with benzodiazepine receptors. Science. 216:1982;1241-1243.
11. 3H]DMCM, a convulsive benzodiazepine ligand, to rat brain membranes. Preliminary studies. J. Neurochem. 41:1983;454-465.
12. A receptor subunit expression. Neuron. 19:1997;1103-1114.
13. Concas A., Mostallino M.C., Porcu P., Follesa P., Barbaccia M.L., Trabucchi M., Purdy R.H., Grisenti P., Biggio G. Role of brain allopregnanolone in the plasticity of γ-aminobutyric acid type A receptor in rat brain during pregnancy and after delivery. Proc. Natl. Acad. Sci. U. S. A. 95:1998;13284-13289.
14. A receptor modulators. J. Pharmacol. Exp. Ther. 273:1995;241-247.
15. Dazzi L., Serra M., Seu E., Cherchi G., Pisu M.G., Purdy R.H., Biggio G. Progesterone enhances ethanol-induced modulation of mesocortical dopamine neurons: antagonism by finasteride. J. Neurochem. 83:2002;1103-1109.
16. A receptor subunit peptide levels in rat cortex during chronic ethanol consumption and withdrawal. J. Neurochem. 69:1997;126-130.
17. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U. S. A. 85:1988;5274-5278.
18. A receptor subunit mRNA expression by hypothalamic magnocellular neurons in the adult rat. J. Neurosci. 16:1996;4872-4880.
19. File S.E. Tolerance to the behavioural actions of benzodiazepines. Neurosci. Biobehav. Rev. 9:1985;113-121.
20. A receptor complex during pregnancy and after delivery in the rat brain. Eur. J. Neurosci. 10:1998;2905-2912.
21. A receptor expression and function during progesterone treatment and withdrawal. Mol. Pharmacol. 57:2000;1262-1270.
22. 4 subunit gene induced by withdrawal of, but not by long-term treatment with, benzodiazepine full or partial agonists. Brain Res. Mol. Brain Res. 92:2001;138-148.
23. A receptor gene expression induced by withdrawal of, but not by long-term exposure to, zaleplon or zolpidem. Neuropharmacology. 42:2002;191-198.
24. 4 subunit mRNA abundance induced by ethanol withdrawal in cerebellar granule cells. Mol. Pharmacol. 63:2003;896-907.
25. A receptor regulation. Chronic treatment with pregnenolone uncouples allosteric interaction between steroid and benzodiazepine recognition sites. Mol. Pharmacol. 44:1993;191-197.
26. A receptor regulation: heterologous uncoupling of modulatory site interactions induced by chronic steroid, barbiturate, benzodiazepine, or GABA treatment in culture. Brain Res. 707:1996;100-109.
27. Fry J., Scharf M., Mangano R., Fujimori M. Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. Zaleplon Clinical Study Group. Int. Clin. Psychopharmacol. 15:2000;141-152.
28. Gallager D.W., Lakoski J.M., Gonsalves S.F., Rauch S.L. Chronic benzodiazepine treatment decreases postsynaptic GABA sensitivity. Nature. 308(5954):1984;74-77.
29. Gallager D.W., Malcolm A.B., Anderson S.A., Gonsalves S.F. Continuous release of diazepam: electrophysiological, biochemical and behavioral consequences. Brain Res. 342(1):1985;26-36.
30. Genazzani A.R., Petraglia F., Bernardi F., Casarosa E., Salvestroni C., Tonetti A., Nappi R.E., Luisi S., Palumbo M., Purdy R.H., Luisi M. Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences. J. Clin. Endocrinol. Metab. 83:1998;2099-2103.
31. Gessa G.L., Muntoni F., Collu M., Vargiu L., Mereu G. Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area. Brain Res. 348:1985;201-203.
32. Girdler S.S., Straneva P.A., Light K.C., Pedersen C.A., Morrow A.L. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol. Psychiatry. 49:2001;788-797.
33. Goldman-Rakic P.S. Circuitry of the primate prefrontal cortex and the regulation of behavior by representational memory. Plum F. Handbook of Physiology: The Nervous System. Higher Functions of the Brain. 1987;373-417 American Physiological Society, Bethesda, MD.
34. Grace A.A. The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. Addiction. 95(Suppl. 2):2000;119-128.
35. A receptors in the acute and chronic effects of ethanol. Psychopharmacology. 139:1998;2-19.
36. A receptor subunit mRNAs in the rat cortex. Neuropharmacology. 35:1996;1457-1463.
37. 2-subunit gene. Mol. Brain Res. 48:1997;164-166.
38. A receptor subunit expression in rat neocortex during tolerance to diazepam. Mol. Pharmacol. 49:1996;822-831.
39. Imperato A., Puglisi-Allegra S., Zocchi A., Casolini P., Angelucci L. Changes in brain dopamine and acetylcholine release during and following stress are independent of the pituitary-adrenocortical axis. Brain Res. 538:1990;111-117.
40. Jentsch J.D., Taylor J.R. Impulsivity results from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology. 146:1999;373-790.
41. Jentsch J.D., Redmond D.E. Jr., Elsworth J.D., Taylor J.R., Youngren K.D., Roth R.H. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science. 277:1997;953-955.
42. Kokate T.G., Banks M.K., Tmagee T., Yamaguchi S., Rogawski M.A. Finasteride, a 5α-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. J. Pharmacol. Exp. Ther. 288:1999;679-684.
43. A receptor function. Trends Pharmacol. Sci. 16:1995;295-303.
44. Low K., Crestani F., Keist R., Benke D., Brunig I., Benson J.A., Fritschy J.M., Rulicke T., Bluethmann H., Mohler H., Rudolph U. Molecular and neuronal substrate for the selective attenuation of anxiety. Science. 290:2000;131-134.
45. Majewska M.D., Harrison N.L., Schwartz R.D., Barker J.L., Paul S.M. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science. 232:1986;1004-1007.
46. Majo-Smith M.F. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. J. Am. Med. Assoc. 278:1997;144-151.
47. McKernan R.M., Rosahl T.W., Reynolds D.S., Sur C., Wafford K.A., Atack J.R., Farrar S., Myers J., Cook G., Ferris P., Garrett L., Bristow L., Marshall G., Macaulay A., Brown N., Howell O., Moore K.W., Carling R.W., Street L.J., Castro J.L., Ragan C.I., Dawson G.R., Whiting P.J. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor α1 subtype. Nat. Neurosci. 3:2000;587-592.
48. A receptors. Brain Res. Rev. 29:1999;196-217.
49. A receptor gene expression. Mol. Pharmacol. 42:1992;415-422.
50. A receptor α subunits reveal that chronic alcohol treatment down-regulates α-subunit expression in rat brain regions. J. Neurochem. 61:1993;1620-1625.
51. A receptor α subunit messenger RNAs in embryonic chick neurons in culture. J. Biol. Chem. 266:1991;6011-6014.
52. Morales A., Aleu J., Ivorra I., Ferragut J.A., Gonzales-Ros J.M., Miledi M. Incorporation of reconstituted acetylcholine receptor from Torpedo into Xenopus oocytes membrane. Proc. Natl. Acad. Sci. U. S. A. 92:1995;8468-8472.
53. A receptor function and expression in brain. Alcohol. 7:1990;237-244.
54. Morrow A.L., VanDoren M.J., Penland S.N., Matthews D.B. The role of GABAergic neuroactive steroids in ethanol action, tolerance and dependence. Brain Res. Rev. 37:2001;98-109.
55. Motzo C., Porceddu M.L., Maira G., Flore G., Concas A., Dazzi L., Biggio G. Inhibition of basal and stress-induced dopamine release in the cerebral cortex and nucleus accumbens of freely moving rats by the neurosteroid allopregnanolone. J. Psychopharmacol. 10:1996;266-272.
56. Motzo C., Porceddu M.L., Dazzi L., Sanna A., Serra M., Biggio G. Enhancement by flumazenil of dopamine release in the nucleus accumbens of rats repeatedly exposed to diazepam or imidazenil. Psychopharmacology. 131:1997;34-39.
57. A receptor subunit for benzodiazepine pharmacology. Nature. 338:1989;583-585.
58. Purdy R.H., Morrow A.L., Moore P.H. Jr., Paul S.M. Stress-induced elevations of gamma-aminobutyric acid type A receptor-active steroids in the rat brain. Proc. Natl. Acad. Sci. U. S. A. 88:1991;4553-4557.
59. Rapkin A.J., Morgan M., Goldman L., Brann D.W., Simone D., Mahesh V.B. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet. Gynecol. 90:1997;709-714.
60. Rasgon N., Serra M., Biggio G., Pisu M.G., Fairbanks L., Tanavoli S., Rapkin A. Neuroactive steroid-serotonergic interaction: responses to an intravenous L-tryptophan challenge in women with premenstrual syndrome. Eur. J. Endocrinol. 145:2001;25-33.
61. Reddy D.S., Rogawski M.A. Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy. J. Pharmacol. Exp. Ther. 294:2000;900-915.
62. Rittmaster R.S. Finasteride. N. Engl. J. Med. 330:1994;120-125.
63. Roca D.J., Rozenberg I., Farrant M., Farb D.H. Chronic agonist exposure induces down-regulation and allosteric uncoupling of the γ-aminobutyric acid/benzodiazepine receptor complex. Mol. Pharmacol. 37:1989;37-43.
64. A receptor regulation in culture: altered allosteric interaction following prolonged exposure to benzodiazepines, barbiturates, and methylxanthines. Mol. Pharmacol. 37:1990;710-719.
65. Romeo E., Ströhle A., Spalletta G., di Michele F., Hermann B., Holsboer F., Pasini A., Rupprecht R. Effects of antidepressant treatment on neuroactive steroids in major depression. Am. J. Psychiatry. 155:1998;910-913.
66. A receptors. Neuropharmacology. 31:1992;693-700.
67. Sanger D.J., Morel E., Perrault G. Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem. Eur. J. Pharmacol. 313:1996;35-42.
68. A receptors in Xenopus oocytes injected with rat brain synaptosomes. J. Neurochem. 67:1996;2212-2214.
69. A receptors induced by degeneration of the striatonigral GABAergic pathway: an electrophysiological study of receptors incorporated into Xenopus oocytes. J. Neurochem. 70:1998;2539-2544.
70. A receptor function in rat brain. J. Neurochem. 75:2000;732-740.
71. 4 subunit suppression prevents withdrawal properties of an endogenous steroid. Nature. 392:1998;926-930.
72. A receptors induced by degeneration of the striatonigral GABAergic pathway: an electrophysiological study of receptors incorporated into Xenopus oocytes. J. Neurochem. 70:1998;2539-2544.
73. Steffensen S.C., Svingos A.L., Pickel V.M., Henriksen S.J. Electrophysiological characterization of GABAergic neurons in the ventral tegmental area. J. Neurosci. 18(19):1998;8003-8015.
74. Sutton S.K., Davidson R.J. Prefrontal brain asymmetry: a biological substrate of the behavioral approach and inhibition systems. Am. Psychol. Soc. 8:1997;204-210.
75. 1 GABA(A) receptor subtype. Proc. Natl. Acad. Sci. U. S. A. 22:2001;6464-6469.
76. Trapani G., Dazzi L., Pisu M.G., Seu E., Biggio G. A rapid method for obtaining finasteride, a 5α-reductase inhibitor, from commercial tablets. Brain Res. Protoc. 9(2):2002;130-134.
77. Troy S.M., Lucki I., Unruh M.A., Cevallos W.H., Leister C.A., Martin P.T., Furlan P.M., Mangano R. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. J. Clin. Psychopharmacol. 20:2000;328-337.
78. Tzschentke T.M. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog. Neurobiol. 63:2001;241-320.
79. Uzunova V., Sheline Y., Davis J.M., Rasmusson A., Uzunov D.P., Costa E., Guidotti A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc. Natl. Acad. Sci. U. S. A. 95:1998;3239-3244.
80. VanDoren M.J., Matthews D.B., Janis G.C., Grobin A.C., Devaud L.L., Morrow A.L. Neuroactive steroid 3α-hydroxy-5α-pregnan-20-one modulates electrophysiological and behavioral actions of ethanol. J. Neurosci. 20(5):2000;1982-1989.
81. Weiss F., Porrino L.J. Behavioral neurobiology of alcohol addiction: recent advances and challenges. J. Neurosci. 22:2002;3332-3337.
82. 4 subunit expressed in Xenopus laevis oocytes. Mol. Pharmacol. 50:1996;1364-1375.
83. Wu F.S., Gibbs T.T., Farb D.H. Inverse modulation of gamma-aminobutyric acid- and glycine-induced currents by progesterone. Mol. Pharmacol. 37:1990;597-602.
84. Yu R., Follesa P., Ticku M.K. Down-regulation of the GABA receptor subunit mRNA levels in mammalian cultured cortical neurons following chronic neurosteroid treatment. Mol. Brain Res. 41:1996;163-168.
85. A response and its potentiation by modulators in cortical neurons. Brain Res. 706:1996;160-162.